November 7, 2019 09:31 AM ESTUpdated 01:33 PM

Roche abandons anti-myostatin approach to Duchenne MD — one more nail in the class' coffin

Amber Tong

Roche has joined a line of drugmakers retreating from one class of experimental Duchenne muscular dystrophy drugs, dealing another blow to the theory that inhibiting myostatin can slow the muscle-wasting disease.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche abandons anti-myostatin approach to Duchenne MD — one more nail in the class' coffin

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Roche aban­dons an­ti-myo­statin ap­proach to Duchenne MD — one more nail in the class' cof­fin

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Roche abandons anti-myostatin approach to Duchenne MD — one more nail in the class' coffin

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Soleno’s rare pediatric disease drug faces PDUFA delay by three months